AbbVie Inc. (ABBV) Extends Rinvoq Patent to 2037, Delaying Generics

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. AbbVie Inc. stands second among them. AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader known for therapies across immunology, oncology, and neuroscience, recently secured a major development for its immunology portfolio. On September 11, 2025, the company announced a settlement with all generic manufacturers challenging Rinvoq (upadacitinib), extending its U.S. patent protection and exclusivity until 20 ...